SMMT - Summit Therapeutics Inc.
NEXT EARNINGS:
May 7, 2026
EPS Est: $-0.12
|
Rev Est: $1.6M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$26.00
DETAILS
HIGH:
$40.00
LOW:
$16.00
MEDIAN:
$24.00
CONSENSUS:
$26.00
UPSIDE:
61.29%
Market Cap:
12.00B
Volume:
2,532,983
Avg Volume:
2,643,231
52 Week Range:
13.83-36.91
Sector:
Healthcare
Industry:
Biotechnology
Beta:
-1.43
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
159
IPO Date:
2015-03-05
EPS (TTM):
-1.44
P/E Ratio:
-12.11
Revenue (TTM):
N/A
Total Assets:
751.18M
Total Debt:
20.89M
Cash & Equiv:
225.27M
Rev Growth (5Y):
-100.0%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
N/A
Debt/Equity:
0.03
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-23 | $-0.14 | $-0.22 | +36.4% | — | $76.6M | — |
| 2025-08-11 | $-0.76 | $-0.09 | -736.9% | — | — | — |
| 2025-05-01 | $-0.09 | $-0.09 | +3.2% | — | — | — |
| 2025-02-24 | $-0.08 | $-0.08 | +2.2% | — | — | — |
| 2024-10-30 | $-0.08 | $-0.07 | -14.3% | — | — | — |
| 2024-08-06 | $-0.05 | $-0.06 | +16.7% | — | — | — |
| 2024-05-01 | $-0.06 | $-0.06 | 0.0% | — | — | — |
| 2023-11-07 | $-0.03 | — | — | — | — | — |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 704,295 | 1.81M | 860,000 | 611,872 | 56.41M | 17.50M | 2.88M | 1.28M | 2.27M |
| Net Income | (1.08B) | (221.31M) | (614.93M) | (78.78M) | (88.60M) | (52.70M) | (23.88M) | 9.87M | (28.53M) | (21.37M) | (24.34M) | (17.12M) |
| EPS | -1.44 | -0.31 | -0.99 | -0.41 | -0.96 | -0.76 | -0.15 | 0.11 | -0.16 | -0.43 | -0.41 | -0.43 |
| Total Assets | 751.18M | 435.56M | 202.95M | 664.17M | 113.37M | 102.50M | 75.46M | 78.39M | 76.38M | 46.98M | 35.71M | 29.22M |
| Total Debt | 20.89M | 7.22M | 106.10M | 518.76M | 2.78M | 465,000 | 699,638 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equivalents | 225.27M | 104.86M | 71.42M | 348.61M | 71.79M | 66.42M | 49.96M | 35.23M | 28.45M | 35.08M | 23.22M | 16.97M |
| Operating Cash Flow | (322.93M) | (142.11M) | (76.76M) | (41.58M) | (72.59M) | (48.11M) | (15.56M) | (35.14M) | (20.79M) | 15.18M | (24.47M) | (17.06M) |
| Free Cash Flow | (323.59M) | (142.25M) | (76.89M) | (42.21M) | (72.89M) | (48.53M) | (15.83M) | (35.31M) | (21.47M) | 15.07M | (24.56M) | (17.12M) |
| FCF per Share | -0.43 | -0.20 | -0.12 | -0.22 | -0.79 | -0.70 | -0.48 | -0.41 | -0.33 | 0.24 | -0.42 | -0.43 |
| Book Value | 658.86M | 388.75M | 77.69M | 126.65M | 83.28M | 79.45M | 61.12M | 55.80M | 13.98M | (4.37M) | 30.10M | 22.55M |
| Cash & ST Investments | 713.45M | 412.35M | 186.24M | 348.61M | 71.79M | 66.42M | 49.96M | 35.23M | 28.45M | 35.08M | 23.22M | 16.97M |
| ROC Equity | -1.64 | -0.57 | -7.91 | -0.62 | -1.06 | -0.66 | -0.39 | 0.18 | -2.04 | N/A | -0.81 | -0.76 |